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Abstract 
Ten neuropathological studies, published in 2019, are discussed, which address important aspects of neuroim-
munology and inflammatory brain disease. They include topics related to new mechanisms of inflammation 
and immune mediated neurodegeneration, which are relevant for multiple sclerosis (publications 1 to 4) and 
discuss the role of specific autoantibodies against myelin oligodendrocyte glycoprotein or aquaporin 4 in neu-
romyelitis optica spectrum disorders (publications 5 and 6). Other studies highlight the discovery of new virus 
induced diseases of the nervous system and their relevance for clinical neurology and diagnostic neuropatholo-
gy (publications 7 and 8). Finally, very interesting studies are discussed dealing with microglia and immune 
mechanisms in neurodegeneration (publication 9) and the neuropathological long-term outcome of Aß vaccina-
tion in Alzheimer’s disease (publication 10). All these studies highlight the central role of neuropathology in 
neurological disease research. 
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Introduction 
There is a common belief that it is modern tech-
nology in molecular neurobiology, immunology and 
genetics, which drives progress in the understanding, 
diagnosis and therapy of human diseases of the nervous 
system, while neuropathology is sometimes considered 
an old fashioned and descriptive discipline which has 
little to add. However, very important new insights for 
human disease, achieved during the last years, came 
from neuropathological studies. In the field of neuroim-
munology this included the discovery of new disease 
entities, new insights into the mechanisms of immune 
surveillance of the brain, of brain inflammation and of 
inflammation induced tissue damage in the nervous 
system. Although all these discoveries were based on a 
combined multidisciplinary approach, the interpretation 
of the structural changes in the brain tissue in human 
disease and experimental models, based on neuropatho-
logical competence and experience, was essential to 
draw the correct conclusions. Here I will discuss some 
recent work published during the last months, which 
contributed to a shift in the understanding of disease 
mechanisms.
Review 
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1) Neuronal vulnerability and mul-
tilineage diversity in multiple sclerosis 
(Schirmer et al 2019) 
This study is based on a potentially revolutionary 
technical development. Up to now gene expression was 
performed either on homogenized tissue, which did not 
discriminate spatial, temporal or cellular changes during 
lesion development, or by in situ hybridization, which 
generally only provided information on the expression of 
single genes. Recently new technologies of single nucle-
us RNA sequencing together with multi-color or multi-
channel-based methods of in situ hybridization and im-
munohistochemistry have been developed, which prom-
ise to overcome some of the above listed limitations. 
The study by Schirmer et al (2019) is one of the first to 
apply such technology for the analysis of multiple sclero-
sis (MS) brain tissue and combined this investigation 
with detailed confirmation by in situ hybridization and 
immunohistochemistry. The study supports the im-
portance of meningeal inflammation with high B-
lymphocyte content for cortical lesions, the heterogene-
ous astrocyte and microglia activation in the lesions, the 
loss of oligodendrocytes, the phagocytosis of myelin 
debris in macrophages during lesion activity and the 
importance of oxidative injury as a mechanism of neu-
ronal injury. The most innovative finding is that a distinct 
subpopulation of excitatory neurons is dominantly af-
fected in subpial cortical lesions of MS patients. Thus, 
this study impressively shows that this new technology 
can be applied on autopsy material of the human brain, 
and that the results reliably confirm what has been de-
scribed with conventional technology before (Mahad et 
al 2015, Reich et al 2018). Even the main finding of a 
selective loss of a subset of excitatory neurons in the 
cortex is not surprising, since these cells are dominantly 
located in the outer cortical layers, which have been 
described before to show the most severe neuronal loss 
in subpial lesions (Magliozzi et al 2010). A similar ap-
proach has been used recently to determine oligoden-
drocyte heterogeneity in normal human controls and 
multiple sclerosis patients (Jäkel et al 2019). This study, 
too, showed that this new technology is suitable for the 
analysis of post mortem tissue of human inflammatory 
brain diseases and it reveals a new dimension regarding 
the complexity of cell phenotypes already in the normal 
tissue, being even more complex in multiple sclerosis 
lesions. However, to draw firm conclusions related to 
disease pathogenesis such studies have to be performed 
on much larger samples of patients and lesions and on 
the basis of much more elaborate selection and charac-
terization of different lesion types. Thus, in future stud-
ies such technologies have to be applied on cases and 
lesions, which have been very carefully selected accord-
ing to the specific research question. Unfortunately, 
availability of such material is very limited when the 
technology requires the use of fresh frozen tissue. Thus, 
major efforts are necessary to adapt these new technol-
ogies to formaldehyde fixed and paraffin embedded 
archival material.  
2) Epstein-Barr Virus specific CD8 
T cells selectively infiltrate the brain in 
multiple sclerosis and interact locally 
with virus-infected cells: Clue for a vi-
rus driven immunopathological mech-
anism (Serafini et al 2019) 
Even in the absence of an overt inflammatory dis-
ease of the central nervous system there is a small to 
moderate number of T-lymphocytes present in the brain 
and spinal cord, while infiltration of the tissue by T-cells 
and B-cells is massively increased in inflammatory brain 
diseases. From experimental data in normal mice and 
mouse models of neurodegenerative diseases or auto-
immune encephalomyelitis it was suggested that these 
cells are MHC Class II restricted CD4+ T-cells, which en-
ter the brain in the course of immune surveillance and, 
when directed against autoantigens of the CNS, may 
exert both, disease-promoting as well as regulatory or 
protective functions. These concepts however, were 
difficult to harmonize with previous observations that 
the majority of T-cells in the normal human brain and in 
the CNS of patients with neurodegenerative disease are 
CD8+ MHC class I restricted T-cells, displaying the phe-
notype of tissue resident memory cells (Smolders et al 
2018). Similarly, in the MS brain CD8+ T-cells with a 
phenotype of tissue resident memory cells prevail, 
where they show focally restricted activation in particu-
lar in active lesion (van Nierop et al 2017, Machado 
Santos et al 2018; Figure 1C). So far, such tissue resident 
memory cells have been found, defined and character-
ized in solid tissues, including the brain, and in models of 
virus infection, where they form a very effective barrier 
against re-infection by the same agent (Steinbach et al 
2018). 
Thus, a key question is, what target antigen is rec-
ognized by the CD8+ tissue resident T-cells in the MS 
brain. Multiple sclerosis is regarded by immunologists as 
an autoimmune disease, driven by T-lymphocytes di-
rected against myelin antigen(s). However, attempts to 
identify an MS-specific autoimmune response have so 
far failed (Hohlfeld et al 2016). Even when the investiga-
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tion specifically focused on activated CD8+ T-cells in the 
MS lesions, no reactivity was found against the classical 
candidates of myelin directed autoimmunity, but a sub-
stantial number of isolated T-cells recognized epitopes 
from Epstein Barr virus (EBV; Van Nierop et al 2017, 
Serafini et al 2019). Furthermore, Serafini et al (2019) 
showed that these EBV reactive T-cells form close con-
tacts with B-lymphocytes expressing epitopes of EBV 
related proteins, and these T-cells display CD 107 on 
their surface, suggesting the release of the content of 
their cytotoxic granules. Overall these data suggest that 
the chronic inflammatory response in the MS brains may 
in part be driven by a T-cell response against EBV (Seraf-
ini et al 2019). However, the question whether there is 
productive EBV expression in the MS brain is still contro-
versial. It is described by some groups, while other 
groups using similar techniques in material from compa-
rable disease phenotypes and stages failed to confirm 
the data (van Nierop et al 2017). The reason for these 
discrepancies is still unresolved (Lassmann et al 2011). 
Another recent study (Konjevic Sabolek et al 2019) de-
scribes the interaction of activated CD8+ cytotoxic cells 
with local macrophages, but not with B-cells, which are 
the potential target for EBV infection. Thus, the specific 
antigenic target of T-cells in MS lesions is still unre-
solved, but recent data indicate that the concept of 
autoimmunity against myelin or other CNS antigens may 
be wrong. 
 
Figure 1: One well established and several new mechanisms triggering or propagating inflammation in the central nervous system (CNS) 
A: The basic well-established mechanism of immune surveillance and inflammation of the central nervous system is that T-cells, activat-
ed in the peripheral immune system, are able to pass the blood brain barrier and enter the CNS in the process of immune surveillance. 
When they encounter their specific antigen, presented in the meninges, the perivascular space or the CNS parenchyma they get re-
activated, produce proinflammatory cytokines and attract additional immune cells into the lesion. Red cells: activated T-cells, red ring 
cells: resting T-cells; star like cells: macrophages and microglia involved in antigen presentation; the blue circles indicate the endotheli-
um of the blood brain barrier and the glia limitans. 
B: An alternative way to start inflammation in the CNS (as described by publication 3) is the local presence of damaged tissue or foreign 
antigens from infectious agents (red dots); they interact with microglia and induce inflammasome activation and the production of pro-
inflammatory cytokines (green triangles). These cytokines activate endothelial cells at the blood brain barrier and allow the recruitment 
of T-cells into the focal site of tissue injury. In case these T-cells (red circles) find their cognate antigen within the lesion, they become 
activated (red cells) and trigger the full-blown inflammatory lesion. 
C: In conditions of chronic brain inflammation, such as for instance in multiple sclerosis (as discussed in context with publication 2), high 
numbers of tissue resident memory T-cells (green circles) are present within the brain and lesions and they are mainly in an inactivated 
stage. When there is re-appearance of their cognate antigen (for instance a foreign antigen or a modified self-antigen) presented by 
perivascular B-cells (blue circles) or by macrophages / microglia (blue stars), they get re-activated and propagate the chronic inflamma-
tory process. 
D: A new mechanism of brain inflammation is outlined in publication 6. When high titers of antibodies against aquaporin 4 are present 
in the circulation, the very low amount of antibodies which can pass the normal blood-brain barrier, is sufficient to induce astrocyte 
dysfunction and their pro-inflammatory activation (green cells). This leads to the production of pro-inflammatory cytokines (green trian-
gles), which activate the endothelium and massively disturb the blood brain barrier. This allows more antibodies together with leuko-
cytes (red circles) and complement to enter the perivascular space, to destroy the astrocytes at the glia limitans and to promote in-
flammation. 
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3) Microglia nodules provide the 
environment for pathogenic T cells in 
human encephalitis (Tröscher et al 2019) 
A key question in the pathogenesis of inflammato-
ry brain diseases is, why and how T-cells enter the brain 
and initiate the lesions. One mechanism is that they are 
activated in the peripheral immune system and get ac-
cess to the brain in the course of immune surveillance 
(Wekerle et al 1986; Figure 1A). The other possibility, 
which may be particularly important in conditions of 
virus infection or neurodegeneration, is that local cells in 
the brain, such as for instance microglia, sense focal 
tissue injury and provide signals which drives the initial 
recruitment of CD8+ T-cells into the CNS (Figure 1B). 
Rasmussen’s encephalitis is a rare inflammatory seizure 
disorder mediated by cytotoxic T-cells which attack neu-
rons and astrocytes (Bauer et al 2012). In the study by 
Tröscher et al (2019) it is shown that the initial stage of 
lesion formation is characterized by microglia activation 
and the formation of microglia nodules, which occurs 
before the first CD8+ T-cells have entered the brain. The 
activated microglia initially show inflammasome activa-
tion and up-regulation of endosomal Toll-like receptors, 
which is followed by the production of chemokines, the 
expression of major histocompatibility complex class I 
antigen, the activation of interferon signaling pathways 
and the recruitment of CD8+ T-lymphocytes. These data 
suggest that the initial trigger of inflammatory lesions in 
Rasmussen’s encephalitis is not the passage of activated 
T-cells through the blood brain barrier in the course of 
immune surveillance, but a local cell infection or tissue 
damage, which creates a focal pro-inflammatory envi-
ronment through inflammasome activation. Subsequent-
ly, a subset of these recruited T-cells has to recognize 
their cognate antigen within the CNS to propagate the 
inflammatory reaction. Such a scenario may play a major 
role in the induction of inflammation in viral diseases of 
the nervous system, but similar microglia activation and 
the formation of microglia nodules is also seen around 
active lesions in the MS brain (Burm et al 2016). 
4) Post mortem multiple sclerosis 
lesion pathology is influenced by sin-
gle nucleotide polymorphism (Fransen et 
al 2020) 
Irrespective of the specific antigen, recognized by 
the inflammatory cells in MS lesions, the incidence and 
severity of brain inflammation appears to be influenced 
by the genetic background of the patients. This is now 
well established from genome wide association studies 
(GWAS), which define MS as a disease with a highly 
polygenic background (International Multiple Sclerosis 
Genetics Consortium 2019). More than 200 gene loci 
have been found associated with disease incidence, each 
of them with only very little individual impact. The global 
interpretation of these findings is that MS, as described 
before by pathology, is a chronic inflammatory disease 
of the nervous system, and its likelihood to affect a pa-
tient is influenced by multiple genes which in their inter-
action may enhance pro-inflammatory immune mecha-
nisms. It is likely that such genetic polymorphisms also 
modify the pathological evolution of MS lesions, but 
considering their low impact on the disease in the gen-
eral MS population, it was unexpected that such an 
effect may become apparent in autopsy cohorts. Fran-
sen et al (2020) addressed this question on a material of 
179 MS brains, containing a very high number of very 
well staged and characterized individual MS lesions. On 
this basis they were able to show that certain variants of 
immune related genes, which were before shown to be 
associated with disease severity, were also associated 
with the proportion of active lesions. The respective 
genes were in part related to apoptosis (FAS), T-cell 
activation (CTLA4) or are playing a role both in inflam-
mation and neurodegeneration (CLEC16A). This study 
provides a first hint on how the genetic background of 
MS patients may affect pathological outcome of the 
lesions. However, there are still controversial issues 
regarding the statistical design for such investigations. 
Performing genotype/phenotype correlations with mul-
tiple potential risk associated gene polymorphisms and 
multiple different pathological outcomes requires enor-
mous stringency related to multiple testing, and there is 
some doubt that this can ever be reached with the lim-
ited autopsy material available.  
5) Characterization of human mye-
lin oligodendrocyte glycoprotein anti-
body response in demyelination (Tea et 
al 2019) 
Pathological studies performed during the last 
decade suggest that immunological mechanisms respon-
sible for the induction of MS-like inflammatory demye-
linating lesions are heterogeneous between patients, in 
particular at the early stages of the disease and in pa-
tients with aggressive disease course (Lucchinetti et al 
2000). One subtype of lesions was defined by immuno-
globulin and complement deposition in active lesions 
with initial stages of demyelination. This was interpreted 
as evidence for the involvement of pathogenic autoanti-
bodies, as it is reflected in models of experimental auto-
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immune encephalomyelitis, in which demyelination is 
triggered by antibodies against myelin oligodendrocyte 
glycoprotein (MOG) on the background of a T-cell medi-
ated inflammatory reaction in the brain and spinal cord. 
New technologies, using transfected cell lines, are now 
available to identify potential pathogenic autoantibodies 
and using these techniques it was recently possible to 
identify a subset of patients with inflammatory demye-
linating disease with a systemic antibody response 
against MOG (Borisow et al 2018). Identification of such 
demyelinating anti-MOG antibodies is difficult, since 
they are directed against complex conformational 
epitopes, while antibodies directed against conventional 
linear MOG epitopes are not pathogenic. The study by 
Tea et al (2019) describes the results of a detailed 
epitope mapping, which provides new information on 
the relevant target epitopes, recognized by potentially 
pathogenic MOG auto-antibodies. This is important for 
diagnosis of MOG antibody associated inflammatory 
demyelinating disease and for further analysis of patho-
genetic mechanisms involved in antibody mediated 
demyelination. The identification of pathogenic MOG-
antibodies is a major breakthrough in multiple sclerosis 
research, since current data suggest that the presence of 
anti-MOG antibodies defines an inflammatory demye-
linating disease distinct from MS. It presents with clinical 
features of acute or relapsing disseminated encephalo-
myelitis or neuromyelitis optica and shows a different 
response to current anti-inflammatory treatments (Jari-
us et al 2016). These new findings further suggest that 
the experimental models of autoimmune encephalo-
myelitis more closely reflect MOG antibody associated 
disease than multiple sclerosis itself. 
6) Circulating AQP4-specific auto-
antibodies alone can induce neuromy-
elitis optica spectrum disorder in the 
rat (Hillebrand et al 2019) 
Another disease, which originally has been classi-
fied as a variant of multiple sclerosis, is neuromyelitis 
optica (NMO). However, using similar techniques of 
auto-antibody detection as described above, it became 
clear that the majority of patients with NMO have auto-
antibodies against the astrocytic water channel aqua-
porin 4 (AQP4). Further comprehensive clinical charac-
terization of patients with AQP4 auto-antibodies en-
larged the clinical phenotype, now designated as neu-
romyelitis optica spectrum disorders (NMOSD), which 
are pathologically characterized by a primary inflamma-
tory astrocytopathy with secondary demyelination (Fuji-
hara et al 2019). Experimental studies showed that pa-
tient derived auto-antibodies induce tissue damage in 
vitro or after direct injection into the brain, or when 
systemically injected into animals with T-cell mediated 
autoimmune encephalomyelitis. The study by Hillebrand 
et al (2019) shows for the first time that circulating AQP4 
directed autoantibodies alone can induce NMOSD like 
disease in rats, provided that the injection resulted in a 
very high titer of circulating antibodies with very high 
specificity and affinity. Circulating antibodies reached 
the CNS tissue not only through circumventricular or-
gans but also by the physiological leakage through cere-
bral veins (Figure 1D). Thus, a very low degree of AQP4 
antibody leakage through the intact blood brain barrier 
may target perivascular astrocytes at the perivascular 
glia limitans and may augment further blood-brain barri-
er damage in the course of antibody mediated damage 
of the astrocytic process. This property is unique for 
AQP4 auto-antibodies and not seen with other antibod-
ies such as those directed against MOG. The study fur-
ther shows that brain damage by the leakage of the 
antibody in circumventricular organs is very limited and 
not associated with complement activation, possibly by 
the expression of complement inhibitory proteins. In 
contrast, when present in the perivenous space AQP4 
antibodies induce profound blood-brain barrier injury, 
leakage of complement, recruitment of granulocytes and 
the activation of macrophages, and this gives rise to the 
full pathological spectrum of NMOSD lesions. This study, 
thus, provides some explanation for the heterogeneous 
spectrum of pathology in different brain regions of 
NMOSD patients. 
7) The neuropathology of fatal en-
cephalomyelitis in human Borna virus 
infection (Liesche et al 2019) 
Accurate diagnosis of non-purulent lymphocytic 
encephalitis in humans is a challenge. When no positive 
identification of a specific virus infection is possible, a 
diagnosis of encephalitis of autoimmune or probable 
infectious cause is assigned (Venkatesan and Murphy 
2018, Seilhean 2019). The study by Liesche et al (2019) 
defines a new entity of lymphocytic sclerosing panen-
cephalomyelitis, which is caused by infection with Borna 
disease virus 1 (BoDV-1). Although the disease may fol-
low generalized immunosuppression, in the majority of 
cases it developed spontaneously. The study provides a 
clear account of the pathological features of this new 
disease, consisting of mononuclear cell infiltrates, ede-
ma, microglia activation and the presence of eosinophilic 
spherical inclusion bodies. Virus RNA was detected in 
neurons, ependymal cells, astrocytes and oligodendro-
cytes, but not in lymphocytes, macrophages or micro-
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glia. The distribution of the lesions in the brain and spi-
nal cord was variable ranging from a dominant brain 
stem encephalitis, to prominent affection of the hippo-
campus or a multifocal or diffuse pathology in other 
cases. In addition, infection may also involve the periph-
eral nervous system. This study adds Borna virus infec-
tion to the list of potential causative agents driving an 
acute or subacute inflammatory disease of the central 
and peripheral nervous system, which has to be included 
in the spectrum of clinical differential diagnoses. How 
frequent this condition is in the global population of 
patients with encephalitis has to be determined in the 
future. 
8) Zika virus replicates in adult 
human brain tissue and impairs syn-
apses and memory in mice (Figueiredo et 
al 2019) 
Another recently discovered disease of the nervous 
system is associated with Zika virus infection. Although 
originally believed to disturb brain development in the 
course of intrauterine infection (Counotte et al 2019), it 
became clear in the last years that it may also infect the 
adult human nervous system and give rise to inflamma-
tory diseases of the central and peripheral nervous sys-
tem (da Silva et al 2017). The underlying mechanisms 
were up to now not defined. In this study the authors 
show that Zika virus can infect neurons and replicate not 
only in the human, but also in the mouse brain tissue in 
vitro. This allowed to study in more detail the conse-
quences of Zika virus brain infection. In the mouse it 
mainly accumulates in memory associated brain regions, 
such as for instance the hippocampus, where it induces 
disturbances of long-term potentiation and impairs 
memory. These effects are associated and possibly me-
diated by microglia activation with the up-regulation of 
pro-inflammatory cytokines and the complement com-
ponents C1q and C3. In line with this view it was also 
found that blockade of microglia activation or neutraliza-
tion of TNF-α prevented synapse and memory dysfunc-
tion. These findings suggest that analysis of cognitive 
disturbances in Zika virus infected patients should be 
performed in a more systematic manner. However, it 
has also to be noted that similar mechanisms of cytokine 
and microglia activation associated synapse and memory 
disturbance occur in many different inflammatory condi-
tions of the central nervous system, including even ex-
perimental autoimmune encephalomyelitis (Musella et 
al 2016). It is, thus, rather a general consequence of 
brain exposure to pro-inflammatory cytokines. Whether 
the mechanisms inducing synaptic dysfunction are dif-
ferent and specific in Zika virus infected brain has to be 
clarified in the future by direct comparison. 
 
Figure 2: Microglia Activation in Neurodegeneration and Brain Inflammation 
The normal brain is populated by so called resting or homeostatic microglia. When they sense neurodegeneration, they become activat-
ed through the TREM2/APOE pathway. In this activation state there are phagocytic cells responsible for the removal of tissue debris, 
which is essential to limit further injury and to allow tissue repair. When these activated microglia are further exposed to inflammatory 
cytokines, they differentiate into immunological effector cells, which are actively involved in tissue damage. Thus, both, an impairment 
of the initial step of microglia activation as well as the proinflammatory activation are detrimental for the brain. 
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9) Impact of TREM2 risk variants 
on brain region-specific immune acti-
vation and plaque microenvironment 
in Alzheimer’s disease patient brain 
samples (Prokop et al 2019) 
For many years our views on the pathogenesis of 
Alzheimer’s disease focused on protein misfolding and 
deposition of Aß and tau in the extracellular space or in 
the neuronal cytoplasm. In recent years, however, evi-
dence accumulated that elements of the innate immune 
system may play a role in promoting the cognitive dis-
turbance in patients and the neuropathological damage 
in the brain. In particular, recent genome wide associa-
tion studies identified polymorphisms of genes involved 
in microglia activation to be associated with the disease 
(Sims et al 2017). One of these genes is the TREM2 re-
ceptor (Johnsson et al 2013), which when activated by 
neurodegeneration triggers initial microglia activation 
through the TREM2 / APOE pathway (Krasemann et al 
2017). Although the role of these molecules in microglia 
activation in general and in experimental models of 
neurodegeneration is well understood, it is important to 
determine the neuropathological effects of the respec-
tive gene variants in Alzheimer’s disease patients. This 
question was addressed by the study of Prokop et al 
(2019). The authors describe that carriers of the respec-
tive TREM2 risk variants had lower numbers of plaque-
associated microglia and this was associated with a 
higher degree of axonal injury and tau pathology in 
comparison to carefully matched Alzheimer’s disease 
patients without these TREM2 variants. In addition, 
microglia senescence was found to be enhanced and 
some global decrease in microglia activation in TREM2 
variant AD cases was apparent. The study clearly under-
lines the difficulty of such an investigation in human 
autopsy material, since such differences only became 
apparent when exactly matched lesion stages were 
compared in patients with similar disease severity. This 
is due to the fact that these gene polymorphisms do not 
enable or prevent AD pathology, but just modify its 
speed of development. Overall, the data suggest that 
impairment of microglia activation not only enhances 
the progression of cognitive impairment, but also pro-
motes axonal degeneration and tau pathology. Whether 
this is due to a reduced neuroprotective function of 
microglia or a reduced clearance of misfolded proteins 
due to impaired phagocytosis remains to be determined 
in the future. 
10) Persistent neuropathological 
effects 14 years following amyloid-ß 
immunization in Alzheimer’s disease 
(Nicoll et al 2019) 
Following promising results, documenting the re-
moval of amyloid plaques in mice after active immuniza-
tion with Aß, a first clinical trial had been initiated al-
most 20 years ago, which was followed by several other 
trials using immunization strategies or the systemic 
application of specific Aß-antibodies (Wisniewski and 
Goni 2014, 2015). The first trial was stopped due to the 
appearance of autoimmune inflammatory disease of the 
central nervous system as a complication of the vaccina-
tion strategy. A detailed analysis of the neuropathology 
of patients who died in the years after the trial suggest-
ed that this vaccination resulted in clearance of Aß-
deposits from the brain in association with the devel-
opment of an Aß antibody response, but that this had no 
significant effect of the progression of dementia (Holmes 
et al 2008). The present study by Nicoll et al (2019) in 
detail describes the neuropathology in relation to the 
clinical outcome seen in 22 patients of this trial, who 
died within 14 years after the immunization. This com-
prehensive analysis provides important insights related 
to the design and outcome of Aß directed immunother-
apies in Alzheimer’s disease. Only 77% of the patients 
included in this cohort had Alzheimer’s disease, while 
dementia in the others was due to different diseases. In 
the AD patients with Aß vaccination the vast majority 
provided evidence for plaque removal and the extent for 
amyloid deposition correlated inversely with the titer of 
antibodies directed against the N-terminal region of Aß, 
documenting the sustained effect of Aß vaccination 
reducing amyloid load. Despite a significantly lower 
extent of neurofibrillary pathology in patients with low 
amyloid load, there was still profound neurofibrillary 
tangle pathology in all cases. In addition, severe cerebral 
amyloid angiopathy was noted in the majority of pa-
tients, irrespective of the effect on Aß plaque removal. 
Progression of dementia was seen in most patients, even 
in those with extensive plaque removal. In conclusion, 
this study impressively documents the value of system-
atic neuropathological studies to monitor clinical de-
mentia trials. It shows that Alzheimer’s disease patients 
can remain plaque-free even for 14 years after active 
immunization, but that this has little effect on tau pa-
thology and the further development of dementia. 
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Conclusion 
In this review a number of recent neuropathologi-
cal studies are presented, which contributed to the dy-
namic change in our understanding of the pathogenesis 
of neuroinflammatory diseases. They highlight and con-
firm that the field of neuropathology occupies a central 
position in human disease research. Experimental mod-
els provide important insights into basic and molecular 
mechanisms, but their relevance for the disease in hu-
mans has to be determined by studying the disease in 
patients. Correct interpretation of the changes occurring 
in damaged tissues requires profound neuropathological 
expertise. 
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